OCON Therapeutics
Tel Aviv, Israel· Est.
Innovative Nitinol‑based intrauterine platform delivering hormone‑free contraception and targeted therapies for women’s health.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
Innovative Nitinol‑based intrauterine platform delivering hormone‑free contraception and targeted therapies for women’s health.
ContraceptionAbnormal Uterine BleedingHeavy Menstrual BleedingEndometriosisUterine FibroidsInfertility
Technology Platform
The IUB® platform uses a Nitinol ball‑shaped intrauterine frame that self‑expands to conform to uterine anatomy, enabling hormone‑free contraception and localized drug delivery with reduced perforation risk.
Opportunities
Expanding into EU markets with CE‑marked products and later pursuing FDA approval could unlock large contraceptive and therapeutic address for women’s health.
Risk Factors
Regulatory hurdles, achieving CE marking, and competition from established IUD manufacturers may delay market entry and revenue generation.
Competitive Landscape
OCON competes with traditional IUD makers such as Bayer (Mirena) and Teva, differentiating through its ball‑shaped Nitinol design and drug‑delivery capability.